Trophos, a French pharmaceutical company, announced results from its phase III trial of Olesoxime.
Trophos Phase III Trial Results Announced
This week Trophos, a clinical stage pharmaceutical company based in France, released results of its phase III, randomized, parallel group, double-blind, placebo-controlled trial Olesoxime. Olesoxime did not show a significant increase in survival versus placebo in patients taking Riluzole. It is hypothesized that because of disease severity by the time of diagnosis, the benefit over Riluzole cannot be identified. Olesoxime was found to be well-tolerated. The trial enrolled 512 patients with ALS at 15 sites in France, Germany, UK, Belgium, and Spain. Olesoxine promotes function and survival of neurons under stressful disease conditions.
Read the press release.